Suzuken : Notice Regarding the Results of Acquisition of Treasury Shares Through ToSTNeT-3
November 17, 2023 at 07:36 am IST
Share
November 15, 2023
Press Release SUZUKEN CO., LTD.
Shigeru Asano, President and CEO (Stock Code: 9987)
Securities Traded: Prime Markets of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange
Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters
Tel.: +81-52-961-2331
Notice Regarding the Results of Acquisition of Treasury Shares Through ToSTNeT-3
With respect to the acquisition of treasury shares announced yesterday (November 14, 2023), Suzuken Co., Ltd. hereby announces that it conducted the acquisition as follows.
Reason for Acquisition of Treasury Shares
To carry out agile capital policy to manage changes in the business environment
Acquisition Details
(1) Type of shares acquired
Common shares
(2) Total number of shares acquired
2,800,000 shares
(3) Acquisition price
¥4,861 per share
(4) Total acquisition value
¥13,610,800,000
(5) Acquisition date
November 15, 2023
(6) Acquisition method
Acquisition through Trading Network Off-
Auction Own Share Repurchase Trading
System (ToSTNeT-3) at the Tokyo Stock
Exchange
(Reference)
1. Details of Resolution to Acquire Treasury Shares (Announced on November 10, 2023)
(1) Type of shares to be acquired
Common shares
(2) Total number of shares to be acquired
6,000,000 shares (upper limit)
(% to total number of shares outstanding
(excluding treasury shares): 7.24%)
(3) Total acquisition value of shares
¥25 billion (upper limit)
(4) Acquisition period
November 13, 2023 to March 8, 2024
(5) Acquisition method
Market purchase including Tokyo Stock
Exchange Trading Network Off-Auction Own
Share Repurchase Trading System (ToSTNeT-
3)
2. Total number of treasury shares acquired based on the above resolution (as of November 15, 2023)
(1) Total number of shares acquired
2,800,000 shares
(2) Total acquisition value of shares
¥13,610,800,000
This is an English translation of a statement written initially in Japanese and is provided for reference purposes only. The Japanese original shall prevail in the event of any discrepancy between this document and the original.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Suzuken Co. Ltd. published this content on 15 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2023 02:04:15 UTC.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.